REN and atrial fibrillation: Studies have confirmed that renin–angiotensin system (RAS) inhibitors can reduce the load of atrial fibrillation to some extent, delay the progression of the disease to persistent atrial fibrillation, regulate the expression and functional status of connexin, and inhibit the abnormal distribution of connexin in a pathological state [33,34].